Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Inclusion Criteria: First cohort (newly diagnosed patients): * Age ≥18 years * Newly diagnosed patients with Ph+ CML in CP, with or without the presence of other cytogenetic abnormalities at the time of diagnosis * Treatment naïve patients with confirmed diagnosis within 3 months of study enrolment * Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit of the normal range, and serum creatinine ≤1.5 times the upper limit of the normal range * Written informed consent Second cohort (switched patients): * Age ≥18 years * Ph+ CML patients in CP currently treated with Glivec®, with or without the presence of other cytogenetic abnormalities at the time of switch * Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit of the normal range and serum creatinine ≤1.5 times the upper limit of the normal range * Written informed consent Exclusion Criteria: * CML in accelerated phase (AP) at enrollment except patients in AP with the presence of other cytogenetic abnormalities at the time of diagnosis * CML in BP at enrollment * Patients who meet any of the contraindications to the administration of the study drug according to the approved Summary of Product Characteristics